The story appears on

Page A11

August 2, 2016

GET this page in PDF

Free for subscribers

View shopping cart

Related News

Home » Business » Finance

GSK and Google parent to fight diseases

GLAXOSMITHKLINE and Google parent Alphabet’s life sciences unit are creating a new company focused on fighting diseases by targeting electrical signals in the body, jump-starting a novel field of medicine called bioelectronics.

Verily Life Sciences — known as Google’s life sciences unit until last year — and Britain’s biggest drugmaker will together contribute 540 million pounds (US$715 million) over seven years to Galvani Bioelectronics, they said yesterday.

The new company, owned 55 percent by GSK and 45 percent by Verily, will be based at GSK’s Stevenage research center north of London, with a second research hub in South San Francisco.

It is GSK’s second notable investment in Britain since the country voted to leave the European Union in June. Last week it unveiled plans to spend 275 million pounds on drug manufacturing.

Galvani will develop miniaturized, implantable devices that can modify electrical nerve signals. The aim is to modulate irregular or altered impulses that occur in many illnesses.

GSK believes chronic conditions such as diabetes, arthritis and asthma could be treated using these tiny devices, which consist of a electronic collar that wraps around nerves.

Kris Famm, GSK’s head of bioelectronics research and president of Galvani, said the first bioelectronic medicines using these implants to stimulate nerves could be submitted for regulatory approval by around 2023.

“We have had really promising results in animal tests, where we’ve shown we can address some chronic diseases with this mechanism, and now we are bringing that work into the clinic,” he said.

“Our goal is to have our first medicines ready for regulatory approval in seven years.”

GSK first unveiled its aims in bioelectronics in a paper in the journal Nature three years ago and believes it is ahead of Big Pharma rivals in developing medicines that use electrical impulses rather than traditional chemicals or proteins.

The tie-up shows the growing convergence of healthcare and technology. Verily already has several other medical projects in the works.




 

Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.

沪公网安备 31010602000204号

Email this to your friend